Form D · Biotechnology
QUICKTAKE HEALTH CO
New Orleans, LA · CIK 0001929673
Offering snapshot reported Aug 6, 2026 · SEC filing
- Reported sold
- $2.07M Offering amount: $2.07M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 20, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 6, 2026 | Initial | $2,070,000 | No comparison | 5 | SEC filing |
| Dec 29, 2022 | Initial | $220,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-593298
Source: Form D, filed Aug 6, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Biagas | Director |
| Paige Clayton | Director |
| Andrew Brett Murphy | Director |
| Patrick Pendley | Director |
| Douglas Rand Ragusa | Executive |
| Rand Ragusa | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1441 Canal Street Suite 324
New Orleans, LA, 70112
Phone: 5047108564
New Orleans, LA, 70112
Phone: 5047108564